Sinomab Bio B
Sinomab Bio B, also known as Sinomab Bioscience, is a prominent biopharmaceutical company headquartered in Hong Kong. Founded in 2016, the company has rapidly established itself in the biotechnology sector, focusing on the development of innovative therapies for autoimmune diseases and cancer. With a strong operational presence in Asia and expanding into global markets, Sinomab Bio B is recognised for its unique monoclonal antibody products, which leverage advanced technologies to enhance efficacy and safety. The company has achieved significant milestones, including successful clinical trials that underscore its commitment to addressing unmet medical needs. Sinomab Bio B's strategic position in the biopharmaceutical landscape is marked by its dedication to research and development, making it a key player in the industry.
DitchCarbon Score
How does Sinomab Bio B's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Sinomab Bio B's score of 26 is lower than 50% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Sinomab Bio B's reported carbon emissions
In 2022, Sinomab Bio B, headquartered in Hong Kong, reported total carbon emissions of approximately 4,618,000 kg CO2e. This figure includes 58,000 kg CO2e from Scope 1 emissions, primarily from stationary combustion, and a significant 4,537,000 kg CO2e from Scope 2 emissions, which are mainly attributed to purchased electricity and steam. Additionally, the company recorded 23,000 kg CO2e in Scope 3 emissions, predominantly from business travel. Comparatively, in 2021, the total emissions were about 4,695,590 kg CO2e, with Scope 1 emissions at 69,010 kg CO2e and Scope 2 emissions at 4,626,580 kg CO2e. Notably, Sinomab Bio B has not set any specific reduction targets or climate pledges, indicating a potential area for future commitment to sustainability. The emissions data is not cascaded from any parent organization, and all figures are independently reported by Sinomab Bio B. The company has disclosed emissions across all relevant scopes, demonstrating transparency in its environmental impact reporting.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 69,010 | 00,000 |
| Scope 2 | 4,626,580 | 0,000,000 |
| Scope 3 | - | 00,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Sinomab Bio B is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
